Skip to main content
About the Institute
  • English
  • Français
  • Español

Breadcrumb

  1. Home
  2. Microbiota 3 - March 2018
  3. Report of the 30th congress of the european Helicobacter and microbiota study group
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Microbiota 3 - March 2018
  3. Report of the 30th congress of the european Helicobacter and microbiota study group
Gastroenterology

Report of the 30th congress of the european Helicobacter and microbiota study group

Drug

Congress review

By Pr. Francis Mégraud
Bacteriology laboratory Hôpital Pellegrin, Bordeaux, France

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

Sections

Bandeau4_microbiota3-FR

About this article

Created 26 August 2021
Updated 23 September 2021

The 30th Congress of the European Helicobacter and Microbiota Study Group was held on September 7-9, 2017, in Bordeaux, France, where the first gathering of this group was held in 1988. An important new addition was the inclusion of the topic of gut microbiota, including a post-graduate course on “Antibiotherapy and the gut – New concepts”; a master class on microbiota and several symposia and workshops on the topic.

The key contribution of culturomics

The first presentation of the postgraduate course was provided by D. Raoult from Marseille, France, who revisited the concept of gut microbiota using culturomics. Studies using 16S rDNA sequencing and metagenomics have opened the field, but these techniques have limitations due to discrepancies that may arise at the level of DNA extraction, sequencing, and bioinformatic analysis, moreover, these techniques are missing minority partners. However, the emergence of the concept of culturomics has enabled the discovery of an important number of new bacterial species, Archae, as well as large viruses, which could not be detected by metagenomic analyses. This approach employed by D. Raoult was initially extremely cumbersome (using 200 different media), but is now more straightforward, using only 17 media, and new bugs continue to be discovered every week.

Gut microbiota and antibiotics

The second talk was also fascinating. M. Blaser (New York, NY, USA) presented the suspected link between gut microbiota disturbances and several chronic diseases for which the aetiology is still doubtful, such as asthma, obesity, diabetes, inflammatory bowel disease, etc. The prevalence of these diseases is increasing worldwide and parallels the increased use of antibiotics. There are now data showing that bacteria that have co-evolved with humans are crucial to their good health. There is an age window when the microbiota is established (0-3 years), and consumption of antibiotics at this age may lead to the disappearance of part of the microbiota and therefore the bacterial diversity which is an important criterium for health. Experiments in mice have shown that antibiotics can modify the composition of gut microbiota leading to increased adiposity and modification of the immune response, favouring several diseases.

With the description of the association between gut dysbiosis and several diseases at present, an interesting approach to consider is how to limit the impact of antibiotics on gut microbiota. A first step is to add probiotics to antibiotic treatments, however, all probiotics are not equal. Saccharomyces boulardii appears to be the leader in this area. All studies have shown a beneficial effect of this yeast on antibiotic-related diarrhoea. Among Lactobacilli, there is one emerging species in this respect; Lactobacillus rhamnosus GG, as revealed by H. Sokol.

Non-probiotic approaches

There are currently non-probiotic approaches to prevent gut dysbiosis which were presented by A. Andremont (Paris, France). Indeed, antibiotics are absorbed in the small intestine and their negative effects on gut microbiota occur essentially in the colon. Thus, first attempts were made to deliver β-lactamase to the colon to avoid the effect of β-lactam antibiotics, and subsequently other alternatives using specifically coated absorbent-like activated charcoal. Experiments in mice and dogs have been successful, especially for fluoroquinolone antibiotics.

Once dysbiosis is established, restoration is possible by faecal microbiota transplantation (FMT). It is possible to successfully treat Clostridium difficile infection using allogenic FMT. Autologous transplantation could be an option in the case of planned antibiotic treatment and would be more acceptable given that the risk of unknown pathogens would be avoided. For FMT, there is a need for common legislation in Europe as well as standardization of the process.

Tags
Gastroenterology Antibiotics H Pylori EHSMG

en_view en_sources

    Focus
    Microbiota 3 - March 2018
    • Overview
      • Antibiotic treatment in infants: short and long-term consequences of the microbiome
    • Commented articles
      • Improvement in insulin sensitivity after faecal microbiota transplant depends on the initial microbiota composition of recipients
      • Stool contents of colicky infants induce visceral hypersensitivity in mice
    • Congress review
      • Report of the 30th congress of the european Helicobacter and microbiota study group
      • Focus on the Asian Pacific Digestive Disease Week
    • Press review
      • Intrapartum antibiotic prophylaxis for GBS infection
    Created 26 August 2021
    Updated 23 September 2021

    About this article

    To know more about this topic.

    Main topic

    Drug

    Content type

    Congress review
    Stool contents of colicky infants induce visceral hypersensitivity in mice
    Focus on the Asian Pacific Digestive Disease Week
    Focus

    Microbiota 3 - March 2018

    Overview

    Antibiotic treatment in infants: short and long-term consequences of the microbiome

    Commented articles

    Improvement in insulin sensitivity after faecal microbiota transplant depends on the initial microbiota composition of recipients Stool contents of colicky infants induce visceral hypersensitivity in mice

    Congress review

    Report of the 30th congress of the european Helicobacter and microbiota study group Focus on the Asian Pacific Digestive Disease Week

    Press review

    Intrapartum antibiotic prophylaxis for GBS infection
    Gastroenterology
    20.03.2023

    The role of Bifidobacteria in irritable bowel syndrome (IBS)

    Read the article
    14.03.2023

    Positive impact of running on gut microbiota and adolescent depression

    Read the article
    09.03.2023

    Each subtype of Irritable Bowel Syndrome (IBS) has its own dysbiosis

    Read the article
    Parkinson : le microbiote intestinal, chef d’orchestre des mécanismes pathogéniques ?
    27.02.2023

    Does the gut microbiota orchestrate pathogenic mechanisms in Parkinson’s disease?

    Read the article

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irritable Bo...

    Find out more

    Human milk nutrient fortifiers alter the developing gastrointestinal microbiota of very-low-birth-weight infants

    Commented article - Children's section By Pr. Emmanuel M...

    Find out more

    Impact of beer and non alcoholic consumption on the gut microbiota

    By Pr. Bernd SchnablDivision of Gastroenterology, San Diego Digestive Diseases Research Center (SDDRC), UC ...

    Find out more
    Everything you need to know about Microbiota & Immunity
    15.09.2022

    Everything you need to know about Microbiota & Immunity

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    20.03.2023

    The role of Bifidobacteria in irritable bowel syndrome (IBS)

    Read the article
    14.03.2023

    Positive impact of running on gut microbiota and adolescent depression

    Read the article
    09.03.2023

    Each subtype of Irritable Bowel Syndrome (IBS) has its own dysbiosis

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo